J. Pike

A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, K. Swenerton, G. Batist, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.

K. Swenerton, H. Steed, P. Hoskins, 2012, Gynecologic oncology.

Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma.

K. Swenerton, P. Hoskins, J. Pike, 1997, Gynecologic Oncology.

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

K. Swenerton, P. Hoskins, P. Lim, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P a c litaxel a nd C arboplatin, A lone o r W ith I rradiation, i n Advanced o r R ecurrent E ndometrial C ancer: A P hase I I S tudy

K. Swenerton, P. Hoskins, P. Lim, 2001 .

Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy.

K. Swenerton, C. Aquino-Parsons, P. Hoskins, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Parkinson's disease: a review and recommendations for dental management.

G. Paulson, D. E. Jolly, R. Paulson, 1989, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

Small cell carcinoma of the cervix treated with concurrent radiotherapy, cisplatin, and etoposide.

K. Swenerton, P. Hoskins, E. McMurtrie, 1995, Gynecologic oncology.

Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in ‘high-risk’ epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade)

N. Le, K. Swenerton, P. Hoskins, 1994, International Journal of Gynecologic Cancer.

"MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.

K. Swenerton, P. Hoskins, E. McMurtrie, 1996, Gynecologic oncology.